| Dr David Bryan Rhodes Sr, MD | |
|
113 Lielmanis Ave, Hurlburt Field, FL 32544-5613 | |
| (850) 881-2337 | |
| Not Available |
| Full Name | Dr David Bryan Rhodes Sr |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 113 Lielmanis Ave, Hurlburt Field, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063434496 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 016277 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Bryan Rhodes Sr, MD 113 Lielmanis Ave, Hurlburt Field, FL 32544-5613 Ph: (850) 881-2337 | Dr David Bryan Rhodes Sr, MD 113 Lielmanis Ave, Hurlburt Field, FL 32544-5613 Ph: (850) 881-2337 |
News Archive
At the turn of the millennium, the cost to sequence a single human genome exceeded $50 million, and the process took a decade to complete. Microbes have genomes, too, and the first reference genome for a malaria parasite was completed in 2002 at a cost of roughly $15 million. But today researchers can sequence a genome in a single afternoon for just a few thousand dollars. Related technologies make it possible to capture information about all genes in the genome, in all tissues, from multiple individuals.
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.
A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network. This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus.
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
› Verified 9 days ago
Dr. Paul A Tilton, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 113 Lielmanis Ave, Hurlburt Field, FL 32544 Phone: 850-884-3607 | |
Dr. Clayton J Rabens, M.D., M.P.H. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 113 Lielmanis Ave, Hurlburt Field, FL 32544 Phone: 850-881-5210 | |
Dr. Gregory Adam Baker, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 113 Lielmanis Ave, Hurlburt Field, FL 32544 Phone: 850-881-1020 | |
Dr. Daniel Owen Wyman, MD, MPH Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 113 Lielmanis Ave, Hurlburt Field, FL 32544 Phone: 850-884-2269 | |
Dr. Peter Andrew Baldwin, MD, MBA, MPH Family Medicine Medicare: Medicare Enrolled Practice Location: 113 Lielmanis Ave, Hurlburt Field, FL 32544 Phone: 850-881-3307 | |
Shawn Bishop, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 601 Independence Rd, Hurlburt Field, FL 32544 Phone: 850-881-1020 |